Skip to main content

Autoimmune Hepatitis clinical trials at University of California Health

2 in progress, 0 open to eligible people

Showing trials for
  • ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

    Sorry, in progress, not accepting new patients

    VAY736 dose testing; VAY736 efficacy and safety testing.

    at UC Davis

  • Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

    Sorry, in progress, not accepting new patients

    This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allows patients to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.

    at UCLA UCSF

Last updated: